Cedars-Sinai is embracing synthetic data to strengthen its machine learning and artificial intelligence capabilities for research and clinical initiatives. Synthetic data uses AI to generate datasets that reflect real patient characteristics and treatment patterns without exposing private information, enabling faster, privacy-preserving insights that support research and clinical decision-making more efficiently than traditional data retrieval methods.To implement this strategy, Cedars-Sinai partners with Syntho, an AI technology provider from Amsterdam that participated in its Accelerator program, and integrates synthetic data efforts with its new Digital Innovation Platform. Leaders in computational biomedicine at the health system are exploring how synthetic data lowers barriers to research, facilitates collaboration, and accelerates hypothesis testing, while also recognizing limitations in certain data types and the need for careful user communication.